Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06843902 · ClinicalTrials.gov registry record · Phase 2
Improving Coronary Vascular Health in Women
A Phase 2 study of HIV-1-infection and Metabolic Disease, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06843902 is a Phase 2 study of HIV-1-infection and Metabolic Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06843902, a Phase 2 study of HIV-1-infection and Metabolic Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.
Conditions Studied
Interventions
- OTHER Health Education
- OTHER Subspecialty clinic referral
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06843902
The ClinicalTrials.gov registry entry for NCT06843902 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 350-participant average among 71 other HIV-1-infection trials with a reported enrollment target (77% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with HIV-1-infection appearing as the primary indexed condition, and to 2 interventions - of which Health Education is the first listed.
NCT06843902 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06843902 about?
NCT06843902 is a clinical study titled "Improving Coronary Vascular Health in Women". Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small corona...
What is the current status of trial NCT06843902?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-04-17. Estimated completion is 2029-06.
What conditions does trial NCT06843902 study?
This clinical trial studies the following conditions: HIV-1-infection, Metabolic Disease, Coronary Microvascular Dysfunction.
What interventions are being tested in trial NCT06843902?
The interventions under investigation include: Health Education (OTHER), Subspecialty clinic referral (OTHER).
Who is sponsoring clinical trial NCT06843902?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06843902 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
RECRUITING · Phase 2
-
PrEPsmart 2-1-1 Pilot
RECRUITING · Phase 2
-
A Clinical Trial of STP0404 in Adults With HIV-1 Infection
RECRUITING · Phase 2
-
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
RECRUITING · Phase 2
-
Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
RECRUITING · Phase 2
-
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.